GPS Cancer Posters

  1. CMS subtypes characterized by high TMB shows immunosuppressive microenvironment that implies resistance to immunotherapy

  2. Genomic and immune infiltration differences between MSI and MSS GI tumors

  3. Comprehensive-omic analysis of 152 CRC patients allows greater subclassification than CMS or sidedness alone

  4. Clinical trial screening of CDKN2A genomic alterations in patients with Pancreatic cancer and Hepatobiliary cancers requires greater precision than somatic sequencing alone

  5. Comprehensive characterization of immune landscape in gastrointestinal cancers and head and neck cancers via computational deconvolution

  6. Proteomic Analysis of Therapeutic Biomarkers to Guide Treatment of Patients with Bone Metastases
    January 2018, MSACL

  7. Selecting Patients with Stage II or III Colorectal Cancer for 5Fluorouracilbased Adjuvant Chemotherapy Using Proteomic Analysis
    January 2018, ASCOGI

  8. The Prognostic Role of Microsatellite Status, Tumor Mutational Burden, and Protein Expression in Colorectal Cancer
    January 2018, ASCOGI

  9. Identifying Patients Sensitive to AnthracyclineContaining Therapy with Quantitative Proteomic and Genomic Profiling
    December 2017, SABCS

  10. SLFN11 Expression in Early Stage NonSmall Cell Lung Cancer Correlates with Benefit from PlatinumContaining Chemotherapy
    October 2017, 18th World Conference on Lung Cancer

  11. Identifying Responders to Temozolomide Among Patients with Metastatic Colorectal Cancer Using Proteomic Quantitation of MGMT
    June 2017, ASCO

  12. Predicting Overall Survival in Gastric Cancer Patients Randomized to Chemotherapy: A Reevaluation of the ITACAS Trial
    June 2017, ASCO

  13. Proteomic Quantitation of ERCC1 May Predict Response to PlatinumBased Chemotherapy in Patients with NonSmall Cell Lung Cancer
    June 2017, ASMS

  14. Quantitative Proteomic Analysis of MGMT May Predict Response of Colorectal Cancer Patients to Treatment with Temozolomide
    June 2017, ASMS

  15. Quantification of FGFR Protein Expression in Solid Tumors by Targeted Mass Spectrometry and Correlation with FGFR Gene Amplification Status
    June 2017, ASMS

  16. Using “Omics” to Select Immunotherapy and Conventional Therapy Combinations
    April 2017, AACR

  17. Proteomic Analysis of MET Tyrosine Kinase Receptor as a Prognostic Biomarker of Survival in Patients with Gastroesophageal Cancer
    January 2017, MSACL

  18. Entering the Era of Clinical Proteomics: Utilizing Multiplexed Targeted Proteomics to Identify GC Patients Who May Benefit from Docetaxel: Reevaluation of the ITACAS trial
    January 2017, ASCOGI

  19. Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial
    December 2016, 17th World Conference on Lung Cancer

  20. Clinical mass spectrometrybased proteomics unlocks personalized medicine potential from bone metastases
    December 2016,EORTCNCIAACR

  21. Mass spectrometrybased proteomic analysis may improve identification of patients sensitive to FGFR inhibitor therapy
    December 2016, SABCS

  22. Identifying patientspecific neoepitopes for cellbased and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes
    December 2016, SABCS

  23. Identifying Patientspecific Neoepitopes for Cellbased and Vaccine Immunotherapy within the Cancer Genome Atlas Reveals Rarely Shared Recurrent Neoepitopes
    November 2016, SITC

  24. Identifying Patientspecific Neoepitopes for Cellbased and Vaccine Immunotherapy within the Cancer Genome Atlas Reveals Rarely Shared Recurrent Neoepitopes
    November 2016, EORTC

  25. Exploratory study of NQO1 expression in advanced solid tumors.
    June 2016, ASMS

  26. Identifying Patientspecific Neoepitopes for Cellbased and Vaccine Immunotherapy Targets in Breast Cancer Patients by HLA Typing and Predicting MHC Presentation from Whole Genome and RNA Sequencing Data.
    June 2016, ASCO

  27. Highthroughput Identification of Neoepitopes for Development of Patientspecific Cancer Immunotherapies
    April 2016, AACR

  28. Quantitative HER2 protein expression analysis in multiple cancer indications: Identification of candidates for HER2 targeted therapies
    March 2016, TAT

  29. KRASgene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma
    January 2016, ASCOGI

  30. Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial
    December 2015, SABCS

  31. Integrating Whole Exome Sequencing Data with RNASeq And Quantitative Proteomics to Better Inform Clinical Treatment Decisions in Patients with Metastatic Triple Negative Breast Cancer
    December 2015, SABCS

  32. Integrating Whole Genome Sequencing Data With RNAseq, Pathway Analysis, and Quantitative Proteomics to Determine Prognosis After Standard Adjuvant Treatment With Trastuzumab and Chemotherapy in Primary Breast Cancer Patients
    December 2015, SABCS

  33. Whole genome sequencing and quantitative proteomics reveal HPV integration and HER2 overexpression in a patient with cervical cancer: Comprehensive omics analysis driving clinical treatment decisions
    June 2015, AACR Precision Medicine Series

  34. Building patientspecific predictors of drug responses from cell line genomics
    June 2015, AACR Precision Medicine Series

  35. Genomics, Transcriptomics, and Proteomics in the Clinical Setting: Integrating Whole Genome and RNA Sequencing With Quantitative Proteomics to Better Inform Clinical Treatment Selection
    May 2015, ASCO

  36. HER2 Quantification By Targeted Proteomics Compared To IHC Or ISH In Predicting Clinical Benefit From AntiHER2 Therapy In HER2positive Breast Cancer
    May 2015, ASCO

  37. Proteomic analysis of primary and metastatic breast cancers reveals a wide range of expression of the folate receptor, a potential drug target
    May 2015, ASCO

  38. Quantitative measurement of HER2 levels by targeted proteomics predicts survival in gastric cancer patients treated with trastuzumab
    May 2015, ASCO

  39. Diagnostic protein quantitation of actionable targets in patient biopsies using clinical mass spectrometry
    May 2015, ASMS

  40. Her2 expression in gastroesophageal cancer (GEC) FFPE tissue using mass spectrometry (MS) and correlation with HER2 gene amplification
    January 2015, ASCOGI

  41. Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue predicts survival in patients treated with antiHER2 based therapy
    December 2014, SABCS

  42. Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for PDL1 Protein in FFPE NSCLC Samples
    November 2014, EORTCNCIAACR

  43. Quantification of ALK from NonSmall Cell Lung Cancer (NSCLC) FFPE Tissue by Targeted Mass Spectrometry
    October 2014, Chicago Multidisciplinary Symposium in Thoracic Oncology

  44. High Levels of HER2 Measured By Multiplex Mass Spectrometry Correlate With Increased Overall Survival In Patients Treated With AntiHER2 Therapy
    May 2014, ASCO

  45. A comprehensive analysis of molecular profiles across over 10,000 tumor and germline exomes from over 5,000 patients across more than 20 tumor types
    May 2014, ASCO

  46. Differential pathway activation associated with domainspecific PIK3CA mutations
    April 2014, AACR

  47. Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for PDL1 Protein in FFPE NSCLC Samples
    February 2014, IASLC

  48. Towards personalized treatment for gastroesophageal adenocarcinoma: Strategies to address inter and intra patient tumor heterogeneity: PANGEA
    January 2014, ASCOGI

  49. Quantification of MET Expression Using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue
    January 2014, ASCOGI

  50. Multiplexed Mass Spectrometrybased Assay to Quantify Translocation Markers from NSCLC FFPE Tissue
    January 2014, AACRIASLC

  51. Learning Regulatory Interactions with Paradigm
    July 2013, ISBC

  52. Learning regulatory links in cancer through integrated pathway analysis with Paradigm
    June, 2013

  53. Development of a Quantitative Gastroesophageal Cancer SRM assay for Use in FFPE Tumor Tissues
    April 2013, AACR

  54. FOXM1 target genes associated with cell cycle regulation predict breast cancer metastatic outcome
    April 2013, AACR

  55. Quantification of HER2 from Gastroesophageal Cancer (GEC) FFPE Tissue by Mass Spectrometry (MS)
    January 2013, ASCOGI

  56. Mass Spectrometry Based Quantitative Analysis of the HER Family receptors in FFPE Breast Cancer Tissue
    December 2012, SABCS

  57. Singlecell RNA sequencing of paclitaxeltreated breast cancer cell lines to find individual cell response
    December 2012, SABCS

  58. Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multiplex Assay for Use in FFPE Tissues
    November 2012, EORTCNCIAACR

  59. Cancer genome sequencing analysis, storage, discovery and delivery
    April 2012, AACR

  60. Integrated Genomic and Pathway Analysis Reveals Key Pathways across Breast Subtypes
    December 2011, SABCS

Contact Us


Tel: 1.301.977.3654
Email: info@nantomics.com

Let us know how we are doing by completing our Customer Satisfaction Survey – Click Here

To report a product quality issue – Click Here

Stay Connected